Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
J Lipid Res ; 56(4): 936-43, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25632048

ABSTRACT

Sulfatides are found in brain as components of myelin, oligodendrocytes, and neurons but are also present in various visceral tissues. Metachromatic leukodystrophy (MLD) is an inherited lysosomal storage disorder caused by a deficiency of arylsulfatase A, leading to severe white matter disease due to the accumulation of sulfatides and lysosulfatides. To study the physiological role of sulfatides, accessible and sensitive quantitative methods are required. We developed a sensitive LC/MS/MS method to quantify total sulfatide and lysosulfatide content as well as individual molecular species in urine and plasma from MLD patients and plasma and tissues from an MLD mouse model. Our results demonstrate that the method can quantify a wide range of sulfatide concentrations and can be used to quantify total sulfatide content and levels of individual molecular species of sulfatides in tissues, cells, and body fluids. Even though plasma sulfatides and lysosulfatides would seem attractive candidate biomarkers that could possibly correlate with the severity of MLD and be of use to monitor the effects of therapeutic intervention, our results indicate that it is unlikely that the determination of these storage products in plasma will be useful in this respect.


Subject(s)
Blood Chemical Analysis/methods , Psychosine/analogs & derivatives , Sulfoglycosphingolipids/blood , Sulfoglycosphingolipids/urine , Urinalysis/methods , Adolescent , Adult , Aged , Animals , Child , Child, Preschool , Chromatography, Liquid , Female , Humans , Infant , Infant, Newborn , Leukodystrophy, Metachromatic/blood , Leukodystrophy, Metachromatic/pathology , Leukodystrophy, Metachromatic/urine , Male , Mice , Middle Aged , Psychosine/blood , Psychosine/urine , Tandem Mass Spectrometry , Young Adult
2.
J Med Genet ; 52(4): 262-8, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25596309

ABSTRACT

BACKGROUND: Fabry disease (FD), a lysosomal storage disorder caused by α-galactosidase A (GLA) gene variants, has a heterogeneous phenotype. GLA variants can lead to classical FD, an attenuated non-classical phenotype, or no disease at all. This study investigates the value of plasma globotriaosylsphingosine (lysoGb3) to distinguish between these groups. This is of particular importance in the diagnosis of individuals with a GLA variant and an uncertain diagnosis of FD, lacking characteristic features of classical FD. METHODS: Subjects with GLA variants were grouped as classical, non-classical, uncertain or no FD, using strict phenotypical, biochemical and histological criteria. Plasma lysoGb3 was assessed by LC/MS/MS (normal ≤ 0.6 nmol/L). RESULTS: 154 subjects were grouped into classical (38 males (M), 66 females (F)), non-classical (13 M, 14 F), uncertain (5M, 9 F) or no FD (6M, 3F). All subjects with a classical phenotype had elevated lysoGb3 values (M: range 45-150, F: 1.5-41.5). LysoGb3 values in patients with a non-classical phenotype (M: 1.3-35.7, F: 0.5-2.0) were different from healthy controls (M: p<0.01, F: p<0.05), but females overlapped with controls. In the no-FD group, lysoGb3 was normal. CONCLUSIONS: LysoGb3 is a reliable diagnostic tool to discern classical FD from subjects without FD. This study suggests that the same applies to patients with a non-classical phenotype. LysoGb3 values of female patients overlap with controls. Consequently, in uncertain cases, increased lysoGb3 values are very suggestive for FD, but normal values cannot exclude FD. Confirmation in larger cohorts and data on the specificity of small lysoGb3 increases are necessary.


Subject(s)
Fabry Disease/blood , Glycolipids/blood , Sphingolipids/blood , Adolescent , Adult , Aged , Fabry Disease/genetics , Female , Humans , Male , Middle Aged , Phenotype , Trihexosylceramides/blood , Young Adult , alpha-Galactosidase/blood
3.
Clin Chem ; 59(3): 547-56, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23237761

ABSTRACT

BACKGROUND: Biochemical markers that accurately reflect the severity and progression of disease in patients with Fabry disease and their response to treatment are urgently needed. Globotriaosylsphingosine, also called lysoglobotriaosylceramide (lysoGb3), is a promising candidate biomarker. METHODS: We synthesized lysoGb3 and isotope-labeled [5,6,7,8,9] (13)C5-lysoGb3 (internal standard). After addition of the internal standard to 25 µL plasma or 400 µL urine from patients with Fabry disease and healthy controls, samples were extracted with organic solvents and the lysoGb3 concentration was quantified by UPLC-ESI-MS/MS (ultraperformance liquid chromatography-electrospray ionization-tandem mass spectrometry). Calibration curves were constructed with control plasma and urine supplemented with lysoGb3. In addition to lysoGb3, lyso-ene-Gb3 was quantified. Quantification was achieved by multiple reaction monitoring of the transitions m/z 786.4 > 282.3 [M+H](+) for lysoGb3, m/z 791.4 > 287.3 [M+H](+) for [5,6,7,8,9] (13)C5-lysoGb3, and 784.4 > 280.3 [M+H](+) for lyso-ene-Gb3. RESULTS: The mean (SD) plasma lysoGb3 concentration from 10 classically affected Fabry hemizygotes was 94.4 (25.8) pmol/mL (range 52.7-136.8 pmol/mL), from 10 classically affected Fabry heterozygotes 9.6 (5.8) pmol/mL (range 4.1-23.5 pmol/mL), and from 20 healthy controls 0.4 (0.1) pmol/mL (range 0.3-0.5 pmol/mL). Lyso-ene-Gb3 concentrations were 10%-25% of total lysoGb3. The urine concentration of lysoGb3 was 40-480 times lower than in corresponding plasma samples. Lyso-ene-Gb3 concentrations in urine were comparable or even higher than the corresponding lysoGb3 concentrations. CONCLUSIONS: This assay for the quantification of lysoGb3 and lyso-ene-Gb3 in human plasma and urine samples will be an important tool in the diagnosis of Fabry disease and for monitoring the effect of enzyme replacement therapy in patients with Fabry disease.


Subject(s)
Chromatography, Liquid/methods , Fabry Disease/diagnosis , Glycolipids/analysis , Sphingolipids/analysis , Tandem Mass Spectrometry/methods , Adult , Calibration , Carbon Isotopes , Humans , Isotope Labeling , Middle Aged , Reproducibility of Results
4.
PLoS One ; 7(10): e47805, 2012.
Article in English | MEDLINE | ID: mdl-23094092

ABSTRACT

INTRODUCTION: Enzyme replacement therapy (ERT) with alpha-Galactosidase A (aGal A) may cause antibody (AB) formation against aGal A in males with Fabry disease (FD). Anti agalsidase ABs negatively influence globotriaosylceramide (Gb3) reduction. We investigated the impact of agalsidase AB on Gb3 and lysoGb3 and clinical outcome in Fabry patients on ERT. METHODS: Adult male and female patients on ERT for at least one year were included. Urinary Gb3 was measured by HPLC, plasma lysoGb3 by LC-ESI-MS/MS and AB with a neutralization assay. RESULTS: Of the 59 patients evaluable patients, 0/30 females and 17/29 males developed anti-agalsidase antibodies (AB+). Only 3/17 males had transient (low) titers (tolerized). All AB+ patients developed antibodies during the first year of treatment. Change of agalsidase preparation (or dose) did not induce antibody formation. AB+ males had significant less decline in plasma lysoGb3 compared to AB- males (p = 0.04). Urinary Gb3 levels decreased markedly in AB- but remained comparable to baseline in AB+ males (p<0.01). (Lyso)Gb3 reduction in plasma and urine on ERT was correlated with LVmass reduction in females and development white matter lesions and stroke. CONCLUSION: In male patients antibodies against aGal A remained present up to 10 years of ERT. The presence of these antibodies is associated with a less robust decrease in plasma lysoGb3 and a profound negative effect on urinary Gb3 reduction, which may reflect worse treatment outcome.


Subject(s)
Antibodies/blood , Fabry Disease/drug therapy , Fabry Disease/immunology , Globosides/urine , Glycolipids/blood , Sphingolipids/blood , Trihexosylceramides/urine , alpha-Galactosidase/therapeutic use , Adult , Chromatography, High Pressure Liquid , Chromatography, Liquid , Enzyme Replacement Therapy , Fabry Disease/blood , Fabry Disease/urine , Female , Humans , Male , Middle Aged , Neutralization Tests , Spectrometry, Mass, Electrospray Ionization , Tandem Mass Spectrometry , Time , Treatment Outcome , alpha-Galactosidase/pharmacology
5.
Hypertension ; 60(4): 998-1005, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22868390

ABSTRACT

Fabry disease is an X-linked hereditary lysosomal storage disorder attributed to a deficiency of α-galactosidase A leading to increased plasma levels of globotriaosylsphingosine (lysoGb3). The disease presents as a vascular disease, with cerebral, cardiac, and renal complications. Carotid intima-media thickness (IMT), brachial flow-mediated dilation (FMD), pulse wave velocity, and advanced glycation end products were measured in 57 classically affected patients (22 men and 35 women), 55 healthy matched controls (20 men and 35 women), and 10 atypical Fabry disease patients (5 men and 5 women). Most patients received enzyme replacement therapy. In classically affected male patients, brachial FMD was decreased (2.9% [95% CI, 0.8% to 7.9%] versus 5.9% [2.1% to 8.5%] in controls; P=0.01), and carotid IMT was increased (0.67 mm [95% CI, 0.50-0.96 mm] versus 0.59 mm [95% CI, 0.40-0.76 mm] in controls; P=0.01). In women and atypical patients these vascular parameters were comparable with controls. Pulse wave velocity was not different; advanced glycation end products were only slightly increased in atypical patients. In classically affected women, a small increase in lysoGb3 was associated with an increase in IMT independent of age. In the classically affected men, all with increased IMT and high levels of plasma lysoGb3, lysoGb3 levels did not add to a higher IMT, suggestive of a ceiling effect. For FMD, elevated lysoGb3 levels (>7 nmol/L) contributed to a 2.9% lower FMD independent of age and sex (P=0.02). Increased carotid IMT and decreased brachial FMD occur in classic Fabry disease, which is associated with plasma lysoGb3 level independent of age and sex. These observations still exist despite enzyme replacement therapy.


Subject(s)
Fabry Disease/physiopathology , Glycolipids/blood , Sphingolipids/blood , Adult , Aged , Aged, 80 and over , Blood Flow Velocity/physiology , Brachial Artery/diagnostic imaging , Carotid Arteries/diagnostic imaging , Carotid Intima-Media Thickness , Enzyme Replacement Therapy , Fabry Disease/blood , Fabry Disease/diagnostic imaging , Fabry Disease/therapy , Female , Humans , Male , Middle Aged
6.
Anal Bioanal Chem ; 403(6): 1671-83, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22526647

ABSTRACT

Many lysosomal storage diseases are characterized by an increased urinary excretion of glycoconjugates and oligosaccharides that are characteristic for the underlying enzymatic defect. Here, we have used capillary high-performance anion-exchange chromatography (HPAEC) hyphenated to mass spectrometry to analyze free oligosaccharides from urine samples of patients suffering from the lysosomal storage disorders fucosidosis, α-mannosidosis, G(M1)-gangliosidosis, G(M2)-gangliosidosis, and sialidosis. Glycan fingerprints were registered, and the patterns of accumulated oligosaccharides were found to reflect the specific blockages of the catabolic pathway. Our analytical approach allowed structural analysis of the excreted oligosaccharides and revealed several previously unpublished oligosaccharides. In conclusion, using online coupling of HPAEC with mass spectrometric detection, our study provides characteristic urinary oligosaccharide fingerprints with diagnostic potential for lysosomal storage disorders.


Subject(s)
Chromatography, High Pressure Liquid/methods , Chromatography, Ion Exchange/methods , Lysosomal Storage Diseases/urine , Mass Spectrometry/methods , Oligosaccharides/urine , Anion Exchange Resins , Humans
7.
Orphanet J Rare Dis ; 6: 69, 2011 Oct 31.
Article in English | MEDLINE | ID: mdl-22041095

ABSTRACT

BACKGROUND: Enzyme replacement therapy is currently the only approved therapy for Fabry disease. From June 2009 on, viral contamination of Genzyme's production facility resulted in a worldwide shortage of agalsidase beta leading to involuntary dose reductions (approved dose 1 mg/kg/eow, reduced dose 0.5 mg/kg/m), or switch to agalsidase alpha (administered dose 0.2 mg/kg/eow). An assessment report from the European Medicines Agency (EMA) raised serious concerns about an increase in adverse events at lower dosages of agalsidase beta. We determined the influence of the shortage on clinical event incidence and the most sensitive biochemical marker (lysoGb3) in Dutch Fabry patients. METHODS: The incidence of clinical events per person per year was calculated from start of agalsidase beta treatment until the shortage, and was compared to the incidence of clinical events during the shortage period. In addition, plasma lysoGb3, eGFR, quality of life (SF-36) and brief pain inventory (BPI) questionnaires were analysed. RESULTS: All thirty-five Dutch Fabry patients using agalsidase beta (17 males) were included. Mean clinical event incidence was unchanged: 0.15 events per person per year before versus 0.15 during the shortage (p = 0.68). In total 28 clinical events occurred in 14 patients during 4.6 treatment years, compared to 7 events in 6 patients during the 1.3 year shortage period. eGFR and BPI scores were not significantly altered. Two SF-36 subscales were significantly but minimally reduced in females. In males, lysoGb3 increased with a median of 8.1 nM (range 2.5-29.2) after 1 year of shortage (p = 0.001). Increases in lysoGb3 were found in both patients switching to agalsidase alpha and on a reduced agalsidase beta dose. Antibody status, treatment duration or clinical event incidence showed no clear correlation to lysoGb3 increases. CONCLUSIONS: No increase in clinical event incidence was found in the adult Dutch Fabry cohort during the agalsidase beta shortage. Increases in lysoGb3, however, suggest recurrence of disease activity.


Subject(s)
Disease Progression , Fabry Disease/drug therapy , Fabry Disease/physiopathology , Glycolipids/blood , Isoenzymes/administration & dosage , Isoenzymes/supply & distribution , Sphingolipids/blood , alpha-Galactosidase/administration & dosage , alpha-Galactosidase/supply & distribution , alpha-Galactosidase/therapeutic use , Adolescent , Adult , Aged , Drug Administration Schedule , Enzyme Replacement Therapy/methods , Fabry Disease/epidemiology , Female , Humans , Incidence , Isoenzymes/adverse effects , Isoenzymes/therapeutic use , Male , Middle Aged , Netherlands/epidemiology , Treatment Outcome , Young Adult , alpha-Galactosidase/adverse effects
8.
J Inherit Metab Dis ; 34(3): 605-19, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21445610

ABSTRACT

A biomarker is an analyte indicating the presence of a biological process linked to the clinical manifestations and outcome of a particular disease. In the case of lysosomal storage disorders (LSDs), primary and secondary accumulating metabolites or proteins specifically secreted by storage cells are good candidates for biomarkers. Clinical applications of biomarkers are found in improved diagnosis, monitoring disease progression, and assessing therapeutic correction. These are illustrated by reviewing the discovery and use of biomarkers for Gaucher disease and Fabry disease. In addition, recently developed chemical tools allowing specific visualization of enzymatically active lysosomal glucocerebrosidase are described. Such probes, coined inhibodies, offer entirely new possibilities for more sophisticated molecular diagnosis, enzyme replacement therapy monitoring, and fundamental research.


Subject(s)
Antibodies , Biomarkers/analysis , Lipids/analysis , Lysosomal Storage Diseases/diagnosis , Proteins/analysis , Animals , Biomarkers/metabolism , Enzyme Replacement Therapy , Fabry Disease/diagnosis , Fabry Disease/metabolism , Fabry Disease/pathology , Fabry Disease/therapy , Gaucher Disease/diagnosis , Gaucher Disease/metabolism , Gaucher Disease/pathology , Gaucher Disease/therapy , Humans , Lysosomal Storage Diseases/metabolism , Lysosomal Storage Diseases/pathology , Lysosomal Storage Diseases/therapy , Models, Molecular , Proteins/metabolism
9.
Biochim Biophys Acta ; 1812(1): 70-6, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20851180

ABSTRACT

Fabry disease is treated by two-weekly infusions with α-galactosidase A, which is deficient in this X-linked globotriaosylceramide (Gb3) storage disorder. Elevated plasma globotriaosylsphingosine (lysoGb3) is a hallmark of classical Fabry disease. We investigated effects of enzyme replacement therapy (ERT) on plasma levels of lysoGb3 and Gb3 in patients with classical Fabry disease treated with agalsidase alfa at 0.2mg/kg, agalsidase beta at 0.2mg/kg or at 1.0mg/kg bodyweight. Each treatment regimen led to prominent reductions of plasma lysoGb3 in Fabry males within 3 months (P=0.0313), followed by relative stability later on. Many males developed antibodies against α-galactosidase A, particularly those treated with agalsidase beta. Patients with antibodies tended towards smaller correction in plasma lysoGb3 concentration, whereas treatment with high dose agalsidase beta allowed a reduction comparable to patients without antibodies. Pre-treatment plasma lysoGb3 concentrations of Fabry females were relatively low. In all females and with each treatment regimen, ERT gave reduction or stabilisation of plasma lysoGb3. Our investigation revealed that ERT of Fabry patients reduces plasma lysoGb3, regardless of the recombinant enzyme used. This finding shows that ERT can correct a characteristic biochemical abnormality in Fabry patients.


Subject(s)
Enzyme Replacement Therapy/methods , Fabry Disease/drug therapy , Glycolipids/blood , Sphingolipids/blood , Adolescent , Adult , Aged , Antibodies/blood , Antibodies/immunology , Child , Child, Preschool , Drug Administration Schedule , Fabry Disease/blood , Female , Humans , Isoenzymes/therapeutic use , Lipids/blood , Male , Middle Aged , Recombinant Proteins , Treatment Outcome , Young Adult , alpha-Galactosidase/immunology , alpha-Galactosidase/therapeutic use
10.
Ann Neurol ; 68(6): 876-87, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21061399

ABSTRACT

OBJECTIVE: Mucopolysaccharidosis (MPS) IIIA (Sanfilippo syndrome type A) is a lysosomal storage disorder caused by deficiency of the enzyme sulfamidase. Information on the natural course of MPS IIIA is scarce, but is much needed in view of emerging therapies. METHODS: Clinical history and molecular defects of all 110 MPS IIIA patients identified by enzymatic studies in the Netherlands were collected and included in this study. RESULTS: First clinical signs, mainly consisting of delayed speech development and behavioral problems, were noted between the ages of 1 and 6 years. Other symptoms included sleeping and hearing problems, recurrent upper airway infections, diarrhea, and epilepsy. The clinical course varied remarkably and could be correlated with the molecular defects. The frequent pathogenic mutations p.R245H, p.Q380R, p.S66W, and c.1080delC were associated with the classical severe phenotype. Patients compound heterozygous for the p.S298P mutation in combination with 1 of the mutations associated with the classical severe phenotype had a significantly longer preservation of psychomotor functions and a longer survival. Two patients homozygous for the p.S298P mutation, and 4 patients from 3 families heterozygous for 3 missense variants not reported previously (p.T421R, p.P180L, and p.L12Q), showed a remarkably attenuated phenotype. INTERPRETATION: We report the natural history and mutational analysis in a large unbiased cohort of MPS IIIA patients. We demonstrate that the clinical spectrum of MPS IIIA is much broader than previously reported. A significant genotype-phenotype correlation was established in this cohort.


Subject(s)
Genetic Association Studies , Genotype , Phenotype , Adolescent , Adult , Behavioral Symptoms/etiology , Cells, Cultured , Child , Child, Preschool , Cohort Studies , DNA Mutational Analysis , Epilepsy/etiology , Female , Fibroblasts , Hearing Disorders/etiology , Humans , Hydrolases/genetics , Kaplan-Meier Estimate , Male , Middle Aged , Mucopolysaccharidosis III/complications , Mucopolysaccharidosis III/enzymology , Mucopolysaccharidosis III/genetics , Mucopolysaccharidosis III/pathology , Mutation/genetics , Pregnancy , Regression Analysis , Severity of Illness Index , Skin/pathology , Sleep Wake Disorders/etiology , Vision Disorders/etiology , Young Adult
11.
J Inherit Metab Dis ; 33(6): 759-67, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20852935

ABSTRACT

Mucopolysaccharidosis type IIIB (MPS IIIB, Sanfilippo syndrome type B) is a lysosomal storage disorder caused by deficiency of the enzyme N-acetyl-α-D-glucosaminidase (NAGLU). Information on the natural course of MPS IIIB is scarce but much needed in view of emerging therapies. To improve knowledge on the natural course, data on all 52 MPS IIIB patients ever identified by enzymatic studies in the Netherlands were gathered. Clinical data on 44 patients could be retrieved. Only a small number (n = 9; 21%) presented with a classical MPS III phenotype; all other patients showed a much more attenuated course of the disease characterized by a significantly slower regression of intellectual and motor abilities. The majority of patients lived well into adulthood. First signs of the disease, usually mild developmental delay, were observed at a median age of 4 years. Subsequently, patients showed a slowing and eventually a stagnation of development. Patients with the attenuated phenotype had a stable intellectual disability for many years. Molecular analysis was performed in 24 index patients. The missense changes p.R643C, p.S612G, p.E634K, and p.L497V were exclusively found in patients with the attenuated phenotype. MPS IIIB comprises a remarkably wide spectrum of disease severity, and an unselected cohort including all Dutch patients showed a large proportion (79%) with an attenuated phenotype. MPS IIIB must be considered in patients with a developmental delay, even in the absence of a progressive decline in intellectual abilities. A key feature, necessitating metabolic studies, is the coexistence of behavioral problems.


Subject(s)
Phenotype , Algorithms , Cause of Death , Cells, Cultured , Child , Child, Preschool , Delivery, Obstetric/methods , Delivery, Obstetric/statistics & numerical data , Diagnosis, Differential , Female , Humans , Infant , Male , Mucopolysaccharidosis III/classification , Mucopolysaccharidosis III/diagnosis , Mucopolysaccharidosis III/epidemiology , Mucopolysaccharidosis III/mortality , Pregnancy , Registries
12.
FEBS J ; 277(14): 2970-86, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20546307

ABSTRACT

Urine, amniotic fluid and ascitic fluid samples of galactosialidosis patients were analyzed and structurally characterized for free oligosaccharides using capillary high-performance anion-exchange chromatography with pulsed amperometric detection and online mass spectrometry. In addition to the expected endo-beta-N-acetylglucosaminidase-cleaved products of complex-type sialylated N-glycans, O-sulfated oligosaccharide moieties were detected. Moreover, novel carbohydrate moieties with reducing-end hexose residues were detected. On the basis of structural features such as a hexose-N-acetylhexosamine-hexose-hexose consensus sequence and di-sialic acid units, these oligosaccharides are thought to represent, at least in part, glycan moieties of glycosphingolipids. In addition, C(1)-oxidized, aldohexonic acid-containing versions of most of these oligosaccharides were observed. These observations suggest an alternative catabolism of glycosphingolipids in galactosialidosis patients: oligosaccharide moieties from glycosphingolipids would be released by a hitherto unknown ceramide glycanase activity. The results show the potential and versatility of the analytical approach for structural characterization of oligosaccharides in various body fluids.


Subject(s)
Amniotic Fluid/chemistry , Ascitic Fluid/chemistry , Lysosomal Storage Diseases/metabolism , Lysosomal Storage Diseases/urine , Neuraminidase/deficiency , Oligosaccharides/analysis , beta-Galactosidase/deficiency , Carbohydrate Sequence , Cathepsin A/genetics , Chromatography, Ion Exchange , Fetus/metabolism , Glycoside Hydrolases/metabolism , Glycosphingolipids/metabolism , Hexoses/analysis , Humans , Infant , Infant, Newborn/metabolism , Infant, Newborn/urine , Lysosomal Storage Diseases/genetics , Mass Spectrometry , Molecular Sequence Data , Oligosaccharides/chemistry , Oligosaccharides/urine , Oligosaccharides, Branched-Chain/analysis , Oligosaccharides, Branched-Chain/chemistry , Oligosaccharides, Branched-Chain/urine , Sugar Acids/analysis , Urine/chemistry
13.
Hum Mutat ; 31(5): E1348-60, 2010 May.
Article in English | MEDLINE | ID: mdl-20232353

ABSTRACT

Mucopolysaccharidosis III D (Sanfilippo disease type D, MPS IIID) is a rare autosomal recessive lysosomal storage disorder previously described in only 20 patients. MPS IIID is caused by a deficiency of N-acetylglucosamine-6-sulphate sulphatase (GNS), one of the enzymes required for the degradation of heparan sulphate. So far only seven mutations in the GNS gene have been reported. The clinical phenotype of 12 new MPS IIID patients from 10 families was studied. Mutation analysis of GNS was performed in 16 patients (14 index cases). Clinical signs and symptoms of the MPS IIID patients appeared to be similar to previously described patients with MPS III. Early development was normal with onset of behavioral problems around the age of 4 years, followed by developmental stagnation, deterioration of verbal communication and subsequent deterioration of motor functions. Sequence analysis of the coding regions of the gene encoding GNS (GNS) resulted in the identification of 15 novel mutations: 3 missense mutations, 1 nonsense mutation, 4 splice site mutations, 3 frame shift mutations, 3 large deletions and 1 in-frame small deletion. They include the first missense mutations and a relatively high proportion of large rearrangements, which warrants the inclusion of quantitative techniques in routine mutation screening of the GNS gene.


Subject(s)
Mucopolysaccharidosis III/genetics , Sulfatases/deficiency , Sulfatases/genetics , Adolescent , Adult , Child , Child, Preschool , DNA Mutational Analysis , Female , Humans , Male , Mutation/genetics , Phenotype , Young Adult
14.
Eur J Cell Biol ; 89(1): 117-23, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19945768

ABSTRACT

Lysosomal hydrolases catalyze the degradation of a variety of macromolecules including proteins, carbohydrates, nucleic acids and lipids. The biogenesis of lysosomes or lysosome-related organelles requires a continuous substitution of soluble acid hydrolases and lysosomal membrane proteins. The targeting of lysosomal hydrolases depends on mannose 6-phosphate residues (M6P) that are recognized by specific receptors mediating their transport to an endosomal/prelysosomal compartment. The key role in the formation of M6P residues plays the GlcNAc-1-phosphotransferase localized in the Golgi apparatus. Two genes have been identified recently encoding the type III alpha/beta-subunit precursor membrane protein and the soluble gamma-subunit of GlcNAc-1-phosphotransferase. Mutations in these genes result in two severe diseases, mucolipidosis type II (MLII) and III (MLIII), biochemically characterized by the missorting of multiple lysosomal hydrolases due to impaired formation of the M6P recognition marker, and general lysosomal dysfunction. This review gives an update on structural properties, localization and functions of the GlcNAc-1-phosphotransferase subunits and improvements of pre- and postnatal diagnosis of ML patients. Further, the generation of recombinant single-chain antibody fragments against M6P residues and of new mouse models of MLII and MLIII will have considerable impact to provide deeper insight into the cell biology of lysosomal dysfunctions and the pathomechanisms underlying these lysosomal disorders.


Subject(s)
Disease , Health , Mannose/metabolism , Animals , Humans , Mucolipidoses/enzymology , Mucolipidoses/genetics , Phosphorylation , Transferases (Other Substituted Phosphate Groups)/chemistry , Transferases (Other Substituted Phosphate Groups)/genetics , Transferases (Other Substituted Phosphate Groups)/metabolism
15.
Eur J Pediatr ; 167(11): 1305-12, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18521627

ABSTRACT

Clara cell protein (CC16) is an anti-inflammatory protein and a biomarker of pulmonary epithelial cells and alveolocapillary membrane injury in adults. We investigated whether low cord blood concentrations of CC16 are associated with the development of respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD) in preterm infants and the relationship between CC16 and its pro-inflammatory counterpart, the secretory phospholipase A(2) (sPLA(2)) enzyme. CC16 concentration, sPLA(2) activity and IL-6 concentration were measured in cord blood plasma from 79 preterm infants (25 controls, 37 infants who developed RDS and 17 infants who developed BPD). After adjustment for gestational age and Apgar score at 5 min, the CC16 concentration was lower in BPD infants than in preterm controls (p<0.01). sPLA(2) activity was similar in all groups and the IL-6 concentrations were increased in both RDS and BPD infants (p<0.01 and p<0.05, respectively, vs. controls). We conclude that low cord blood CC16 concentrations in preterm infants independently predict the development of BPD. Low CC16 levels may reflect early lung injury, which contributes to the severity of RDS and progress towards BPD. Future studies are needed to assess whether the early administration of recombinant human CC16 in preterm infants with low cord blood CC16 prevents the development of BPD.


Subject(s)
Bronchopulmonary Dysplasia/genetics , Fetal Blood/metabolism , Uteroglobin/genetics , Uteroglobin/metabolism , Apgar Score , Bronchopulmonary Dysplasia/enzymology , Bronchopulmonary Dysplasia/epidemiology , Female , Fetal Blood/immunology , Gestational Age , Humans , Incidence , Infant, Newborn , Infant, Premature , Interleukin-6/immunology , Phospholipases A2, Secretory/metabolism , Predictive Value of Tests , Prospective Studies
17.
Photochem Photobiol ; 84(3): 550-5, 2008.
Article in English | MEDLINE | ID: mdl-18435613

ABSTRACT

Melanin synthesis is an oxygen-dependent process that acts as a potential source of reactive oxygen species (ROS) inside pigment-forming cells. The synthesis of the lighter variant of melanin, pheomelanin, consumes cysteine and this may limit the capacity of the cellular antioxidative defense. We show that tyrosine-induced melanogenesis in cultured normal human melanocytes (NHM) is accompanied by increased production of ROS and decreased concentration of intracellular glutathione. Clinical atypical (dysplastic) nevi (DN) regularly contain more melanin than do normal melanocytes (MC). We also show that in these cultured DN cells three out of four exhibit elevated synthesis of pheomelanin and this is accompanied by their early senescence. By using various redox-sensitive molecular probes, we demonstrate that cultured DN cells produce significantly more ROS than do normal MC from the same donor. Our experiments employing single-cell gel electrophoresis (comet assay) usually reveal higher fragmentation of DNA in DN cells than in normal MC. Even if in some cases the normal alkaline comet assay shows no differences in DNA fragmentation between DN cells and normal MC, the use of the comet assay with formamidopyrimidine DNA glycosylase can disclose that the DNA of the cultured DN cells harbor more oxidative damage than the DNA of normal MC from the same person.


Subject(s)
DNA Damage , Dysplastic Nevus Syndrome/pathology , Melanins/biosynthesis , Melanocytes/radiation effects , Reactive Oxygen Species/metabolism , Ultraviolet Rays/adverse effects , Cells, Cultured , Humans , Melanocytes/cytology , Melanocytes/metabolism , Oxidative Stress/radiation effects , Pigmentation , Risk Factors , Skin/cytology
18.
Proc Natl Acad Sci U S A ; 105(8): 2812-7, 2008 Feb 26.
Article in English | MEDLINE | ID: mdl-18287059

ABSTRACT

Fabry disease is an X-linked lysosomal storage disease caused by deficiency of alpha-galactosidase A that affects males and shows disease expression in heterozygotes. The characteristic progressive renal insufficiency, cardiac involvement, and neuropathology usually are ascribed to globotriaosylceramide accumulation in the endothelium. However, no direct correlation exists between lipid storage and clinical manifestations, and treatment of patients with recombinant enzymes does not reverse several key signs despite clearance of lipid from the endothelium. We therefore investigated the possibility that globotriaosylceramide metabolites are a missing link in the pathogenesis. We report that deacylated globotriaosylceramide, globotriaosylsphingosine, and a minor additional metabolite are dramatically increased in plasma of classically affected male Fabry patients and plasma and tissues of Fabry mice. Plasma globotriaosylceramide levels are reduced by therapy. We show that globotriaosylsphingosine is an inhibitor of alpha-galactosidase A activity. Furthermore, exposure of smooth muscle cells, but not fibroblasts, to globotriaosylsphingosine at concentrations observed in plasma of patients promotes proliferation. The increased intima-media thickness in Fabry patients therefore may be related to the presence of this metabolite. Our findings suggest that measurement of circulating globotriaosylsphingosine will be useful to monitor Fabry disease and may contribute to a better understanding of the disorder.


Subject(s)
Fabry Disease/blood , Glycolipids/blood , Sphingolipids/blood , Adolescent , Adult , Animals , Cell Proliferation/drug effects , Child , Glycolipids/pharmacology , Humans , Male , Mice , Myocytes, Smooth Muscle/cytology , Netherlands , Pedigree , Sphingolipids/pharmacology , alpha-Galactosidase/antagonists & inhibitors
19.
Clin Chem ; 53(4): 742-7, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17332150

ABSTRACT

BACKGROUND: Simple, reproducible assays are needed for the quantification of sphingolipids, ceramide (Cer), and sphingoid bases. We developed an HPLC method for simultaneous quantification of total plasma concentrations of Cer, glucosylceramide (GlcCer), and ceramide trihexoside (CTH). METHODS: After addition of sphinganine as internal calibrator, we extracted lipids from 50 microL plasma. We deacylated Cer and glycosphingolipids by use of microwave-assisted hydrolysis in methanolic NaOH, followed by derivatization of the liberated amino-group with o-phthaldialdehyde. We separated the derivatized sphingoid bases and lysoglycosphingolipids by HPLC on a C18 reversed-phase column with a methanol/water mobile phase (88:12, vol/vol) and quantified them by use of a fluorescence detector at lambda(ex) 340 nm and lambda(em) 435 nm. RESULTS: Optimal conditions in the Solids/Moisture System SAM-155 microwave oven (CEM Corp.) for the complete deacylation of Cer and neutral glycosphingolipids without decomposition were 60 min at 85% power, fan setting 7. Intra- and interassay CVs were <4% and <14%, respectively, and recovery rates were 87%-113%. The limit of quantification was 2 pmol (0.1 pmol on column), and the method was linear over the interval of 2-200 microL plasma. In samples from 40 healthy individuals, mean (SD) concentrations were 9.0 (2.3) micromol/L for Cer, 6.3 (1.9) micromol/L for GlcCer, and 1.7 (0.5) micromol/L for CTH. Plasma concentrations of GlcCer were higher in Gaucher disease patient samples and of CTH in Fabry disease patient samples. CONCLUSIONS: HPLC enables quantification of total Cer, GlcCer, and CTH in plasma and is useful for the follow-up of patients on therapy for Gaucher or Fabry disease.


Subject(s)
Ceramides/blood , Chromatography, High Pressure Liquid , Fabry Disease/diagnosis , Fabry Disease/therapy , Fluorometry , Gaucher Disease/diagnosis , Gaucher Disease/therapy , Glucosylceramides/blood , Humans , Plasma , Reference Values , Trihexosylceramides/blood
20.
Am J Physiol Lung Cell Mol Physiol ; 293(1): L35-44, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17384081

ABSTRACT

Administration of inhaled nitric oxide (iNO) is a potential therapeutic strategy to prevent bronchopulmonary dysplasia (BPD) in premature newborns with respiratory distress syndrome. We evaluated this approach in a rat model, in which premature pups were exposed to room air, hyperoxia, or a combination of hyperoxia and NO (8.5 and 17 ppm). We investigated the anti-inflammatory effects of prolonged iNO therapy by studying survival, histopathology, fibrin deposition, and differential mRNA expression (real-time RT-PCR) of key genes involved in the development of BPD. iNO therapy prolonged median survival 1.5 days (P = 0.0003), reduced fibrin deposition in a dosage-dependent way up to 4.3-fold (P < 0.001), improved alveolar development by reducing septal thickness, and reduced the influx of leukocytes. Analysis of mRNA expression revealed an iNO-induced downregulation of genes involved in inflammation (IL-6, cytokine-induced neutrophilic chemoattractant-1, and amphiregulin), coagulation, fibrinolysis (plasminogen activator inhibitor 1 and urokinase-type plasminogen activator receptor), cell cycle regulation (p21), and an upregulation of fibroblast growth factor receptor-4 (alveolar formation). We conclude that iNO therapy improves lung pathology and prolongs survival by reducing septum thickness, inhibiting inflammation, and reducing alveolar fibrin deposition in premature rat pups with neonatal hyperoxic lung injury.


Subject(s)
Fibrin/metabolism , Lung Diseases/pathology , Nitric Oxide/administration & dosage , Nitric Oxide/therapeutic use , Pneumonia/drug therapy , Administration, Inhalation , Animals , Animals, Newborn , Antioxidants/metabolism , Bronchoalveolar Lavage Fluid/chemistry , Cell Cycle , Fibrinolysis , Gene Expression Regulation , Lung/metabolism , Lung/pathology , Nitric Oxide/pharmacology , Proteins/genetics , Proteins/metabolism , Pulmonary Alveoli/pathology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Wistar , Signal Transduction , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...